We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Rua Life Sciences Plc | RUA | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.20 | 1.77% | 11.50 | 09:48:08 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 11.50 | 11.25 | 12.25 | 11.50 | 11.30 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 01/11/2024 07:55 by z1co Posted by NickE on lse:Good find Jimzi, and often with smaller medical device companies the P/E ratio is usually higher than that of established players. As you say we can't necessarily apply a P/E of around 64 especially as U.S. companies have a higher P/E assigned than UK stocks. Also, the 900k 'fair value' is I assume a temporary boost to the move to profitability although ABISS will accelerate the move to profitability. Regardless, markets look ahead and a value for a high growth medical device company moving to profitability with other increasingly 'oven ready' blue sky products should be a multiple of where we are now. Following on from the Aortech shareholder base, RUA's history has mainly been in the blue sky sector so value investors probably don't have it on their radar. It's almost as if the stock is punished for being both blue sky and a value play. It may be that the 50p plus valuation the stock probably deserves will only come with full or partial acquisition and on that topic some very astute posts from IntraVnus. RUA do tend to drop hints and when they spoke about doubling revenues they didn't allude to the bargain £80k acquisition but the clue was there. Maybe "the Company has changed its financial year end to better guide business planning and international business unit assimilation" is flagging up another acquisition but this time it's RUA itself. I wonder how that would pan out? They would be interested in contract manufacturing and Elast-Eon but would Coloplast have any need for Rua Vascular and Structural Heart? Unless of course they are looking to expand into long-term implants or soft tissue repair. This quarter could get interesting. |
Posted at 30/10/2024 08:59 by cocker Totally agree H. The long line of commercial failures here says it all really. Bill Brown is simply not fit for purpose , just like many of the products he claims are world beaters and yet never come to fruition, unlike the regular fund raises of which some were said not to be coming. So once again, many of the new investors here are starting to learn the hard way with regards to the "Champion of failures", arise Sir William Brown. |
Posted at 30/10/2024 08:26 by rivaldo Today's a difficult day to make judgements based on share price reactions - it could just be one or two investors taking profits from the 10.5p-11p area before the Budget changes later on. Or perhaps someone wedded to success re the heart valve has exited given the comment about the MTA partner's priorities.Personally I'm happiest to see the core trading business apparently thriving with the more speculative elements an added and potentially huge bonus. I see it's started to bounce now anyway. |
Posted at 19/6/2024 10:49 by cocker Almost 10% awarded at rock bottom price and you think any investor should be excited |
Posted at 10/6/2024 12:24 by hedgehog11 Maybe you are right and RUA will assume investors will conclude that final results will come in July. I, however, would expect them to state this as they, and to my knowledge every other AIM listed company (and possible to comply with AIM rules), have done previously. |
Posted at 27/3/2024 13:44 by cocker Bones, you seem like a well educated well read guy, but exactly when will you concede defeat here. Elaston for example is supposed to be world beating coating that has barely gained any traction over many years & that's only part of the business that basically is failing. The carrot has been dangled on many occasions only to find that the only thing that investors can be sure of , is the regular begging bowl to fund Williams lavish lifestyle. |
Posted at 19/12/2023 14:59 by bones Webinar thoughts:I’m always amazed Zoom stays relevant as a business. As is true on many webinars (not just RUA), the broadcast quality sounds like Neil Armstrong’s from the moon in 1969. Most investors seem to have lost interest. Apart from the first, the remaining questions were mine and were somewhat fishing for specifics. Not surprising most were knocked back as any talks going on with industry are not going to be for publication anyway until deals are done, if any. The preamble was a repeat of some of the fund raising presentation summarising the businesses. Ultimately it remains a play on what the new investors have been led to believe in persuading them to invest at this low price. A patient game. Pretend you are an EIS investor with three years minimum to hold. Don’t expect fireworks next month! That way any announcements of note will be a pleasant occurrence… |
Posted at 01/12/2023 13:09 by donalc This is the cold reality.They dont really care about us the small retailer investor. They will have lost quiet a few of us. They will have gained some new institutional investors at new bargain price. I am guessing the board was divided on this. But probably there advisor came in with a we have a short window of oppurtunity and lined up a few investors. Feel really sorry for all the long term investors here who bought in years ago (including me!). Loyality in financial world does not pay. Authentic leaders do not exist. All about the £ sign. Glad I live in a very different world. |
Posted at 24/11/2023 11:01 by drradcliffe What's interesting is Equity Development weren't expecting a trading update. They seemed to think the 20/11/23 Strategy Update replaced a trading update.From their note 21/11/23: "Strategy Update In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update." "Sticking to its objectives In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive." Does this mean the market itself wasn't expecting this trading update? I wonder whether it was a very recent decision to do this in order to stabilise the share price, and specifically on a Friday morning to get rid of the short term traders? If you are going to arrange a small placing, the last thing you want is a highly volatile share price. |
Posted at 21/11/2023 10:19 by edmonda Strategy Update, sticking to its objectives - new note from Equity Development (link here: In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update. In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive. RUA Contract Manufacture, the contract manufacturer of medical devices using implantable fabrics with a biocompatible Elast-Eon coating, is responding to a formal bid request that could result in around £2m in revenues, with much of that recuring on an annual basis. Thus, RUA’s board’s objective of doubling the scale of the contract manufacturing business in the medium term is on track. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
